# T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

> **NCT02659943** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Lymphoma, B-Cell
- Lymphoma, Non-hodgkins

## Interventions

- **BIOLOGICAL:** Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02659943
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-21
- **Primary completion:** 2018-06-12
- **Final completion:** 2022-12-31
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659943, "T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02659943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*